BRAF and adrenal cortex carcinoma: The multi-centre cohort of ACC-mela comprises of 82 stage III-IV patients, collected across all centres, with a numerosity of 46 (56%) of Immune-Checkpoint treated and 36 (44%) of patients treated with Target Therapy, namely BRAF/MEK inhibitors (Table 1).